| Literature DB >> 35539409 |
Chen Yang1,2,3, Xiaoyu Xie4, Hu Tang1,2,3, Xuyan Dong1,2,3, Xiaodong Zhang4, Fenghong Huang1,2,3.
Abstract
Gallic acid (GA) is a polyphenol widely found in numerous fruits and vegetables that has been reported to exert anticancer effects, including apoptosis, against cancer cell lines. However, little is known about the induction of apoptotic effects and the underlying mechanism. We used RNA-seq to examine differentially expressed genes in human colon cancer HCT116 cells after 12 h and 24 h exposure to GA. A total of 792 and 911 genes with known functions showed significantly different expression levels in 12 h and 24 h GA-treated HCT116 cells, respectively. KEGG enrichment analysis showed that the identified genes were involved in pathways such as cholinergic synapse, circadian entrainment, calcium signal processing and transport, arachidonic acid metabolism and the p53 signal pathway. Real-time quantitative PCR was used to validate the reliability of the results obtained by RNA-seq. The results of this study indicate that GA triggers apoptosis in HCT116 cells through obstructing the growth of cells in the early phase treatment by down-regulation of calcium channels and then up-regulation of the intrinsic p53 signal pathway through activation of apoptosis caspases, finally leading to the mitochondrial apoptosis pathway. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35539409 PMCID: PMC9079613 DOI: 10.1039/c8ra00260f
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1The effects of GA on colon carcinoma cell proliferation. (a) The cell viability of HCT116, RKO and SW48 cells treated with GA for 24 h. (b) The cell viability of HCT116 cells treated with GA for 12 h, 24 h and 48 h. Statistically significant differences p < 0.05 and p < 0.01 between different treated cells are denoted by * and ** respectively, “ns” means there was no significant difference between treated and untreated cell.
Fig. 2The effects of GA on apoptosis of HCT116 cells. Cell incubation for 24 h with 0, 25, 50 and 100 μM of GA was followed by analysis using flow cytometry.
Fig. 3Gene expression profiles of HCT116 cells treated with GA. (a) Hierarchical clustering of differentially expressed genes in HCT116 cells based on log10-transformed expression values (RPKM). (b) Principle component analysis (PCA) on the complete transcriptome of HCT116 cells in the GA treatment group (GA group) and control group (C group).
Fig. 4Overview of the differentially expressed genes for each comparison samples. (a) Volcano plots of differentially expressed genes between treated group GA12 with control group C, and treated group GA24 with treated group GA12 (b) Venn diagram depicting the differentially expressed genes common to different experimental exposure time.
Fig. 5GO and KEGG enrichment analysis of differentially expressed genes. (a) Histograms of the top 30 enriched GO terms. Enriched items were selected with a corrected. p-Value 0.05. (b) Scatter plots of the top 20 enriched KEGG pathway terms. Enriched items were measured by the rich factor, q value (q < 0.05) and the number of genes.
The significantly enriched KEGG pathways and the identified genes between treated cells and untreated cellsa
| Gene name | Gene description | GA12- | GA24- | ||
|---|---|---|---|---|---|
| log2 fold change |
| log2 fold change |
| ||
|
| |||||
| PDGFRB | Platelet derived growth factor receptor beta | −1.62 | * | 2.14 | *** |
| P2RX7 | Purinergic receptor P2X 7 | −1.40 | *** | 1.54 | *** |
| PLCD4 | Phospholipase C delta 4 | −1.42 | — | 1.40 | — |
| ORAI3 | ORAI calcium release-activated calcium modulator 3 | −1.56 | *** | 2.07 | *** |
| BDKRB2 | Bradykinin receptor B2 | −2.11 | ** | 1.70 | * |
| PLCB4 | Phospholipase C beta 4 | −1.47 | *** | 1.19 | * |
| CAMK2B | Calcium/calmodulin dependent protein kinase II beta | −1.53 | ** | 2.03 | ** |
| SLC8A2 | Solute carrier family 8 member A2 | −1.30 | ** | 1.27 | *** |
| ADCY4 | Adenylate cyclase 4 | −2.10 | * | — | — |
| CACNA1G | Calcium voltage-gated channel subunit alpha1 G | −1.63 | ** | 1.63 | ** |
| CACNA1A | Calcium voltage-gated channel subunit alpha1 A | −1.63 | ** | 1.82 | ** |
| CACNA1I | Calcium voltage-gated channel subunit alpha1 I | −1.29 | ** | 1.48 | *** |
| PRKCG | Protein kinase C gamma | −1.61 | *** | 1.52 | *** |
|
| |||||
| THBS1 | Thrombospondin 1 | 1.32 | ** | −1.41 | ** |
| SESN3 | Sestrin 3 | −2.18 | ** | 2.48 | ** |
| ADGRB1 | Adhesion G protein-coupled receptor B1 | −1.69 | ** | 1.67 | ** |
| IGFBP3 | Insulin like growth factor binding protein 3 | — | — | 1.49 | * |
| BBC3 | Bcl2 binding component 3 | — | — | 1.02 | *** |
| TP53INP1 | Tumor protein p53 inducible nuclear protein 1 | — | — | 1.97 | *** |
| RASA4 | RAS p21 protein activator 4 | — | — | 1.32 | *** |
|
| |||||
| PLA2G4D | Phospholipase A2 group IVD | −4.11 | *** | 4.17 | *** |
| ALOX5 | Arachidonate 5-lipoxygenase | −1.90 | *** | 1.83 | *** |
| AKR1C3 | Aldo-keto reductase family 1 member C3 | −1.93 | ** | 2.45 | *** |
| ALOX15 | Arachidonate 15-lipoxygenase | −2.30 | ** | 2.44 | ** |
| PTGDS | Prostaglandin D2 synthase | −3.00 | *** | 2.79 | *** |
| GGT5 | Gamma-glutamyltransferase 5 | −1.49 | *** | 1.76 | *** |
| CYP4F2 | Cytochrome P450 family 4 subfamily F member 2 | −2.29 | ** | 2.14 | ** |
|
| |||||
| CHRM4 | Cholinergic receptor muscarinic 4 | −1.20 | *** | 1.33 | *** |
| PLCB4 | Phospholipase C beta 4 | −1.47 | *** | 1.19 | * |
| FOS | Fos proto-oncogene, AP-1 transcription factor subunit | −1.99 | *** | 1.99 | *** |
| GNG13 | G protein subunit gamma 13 | −1.55 | *** | 1.78 | ** |
| CREB3L3 | cAMP responsive element binding protein 3 like 3 | −2.01 | *** | 2.13 | *** |
|
| |||||
| PER2 | Period circadian clock 2 | 1.36 | *** | −1.55 | *** |
| KCNJ5 | Potassium voltage-gated channel subfamily J member 5 | −1.74 | * | — | — |
|
| |||||
| NRG1 | Neuregulin 1 | 1.67 | ** | −1.80 | ** |
| SHC3 | SHC adaptor protein 3 | −2.33 | *** | 2.35 | *** |
| CBLB | Cbl proto-oncogene B | −1.26 | *** | 1.06 | *** |
| JUN | Jun proto-oncogene, AP-1 transcription factor subunit | −1.13 | *** | 1.25 | *** |
| SHC2 | SHC adaptor protein 2 | −1.51 | *** | 1.73 | *** |
| SOS2 | SOS RAS/Rho guanine nucleotide exchange factor 2 | −1.14 | * | 1.35 | ** |
|
| |||||
| MMP9 | Matrix metallopeptidase 9 | −1.76 | *** | 1.77 | *** |
|
| |||||
| LHB | Luteinizing hormone beta polypeptide | −1.84 | *** | 1.62 | ** |
| PLD1 | Phospholipase D1 | −1.59 | *** | 1.82 | *** |
|
| |||||
| CCNG2 | Cyclin G2 | −1.80 | ** | 2.05 | ** |
|
| |||||
| ASIC4 | Acid sensing ion channel subunit family member 4 | −1.20 | ** | 1.15 | ** |
| TRPV4 | Transient receptor potential cation channel subfamily V member 4 | −1.24 | ** | 1.11 | * |
| TRPV2 | Transient receptor potential cation channel subfamily V member 2 | −1.52 | ** | 1.63 | ** |
Significant differences p < 0.05, p < 0.01 and p < 0.001 of log2 fold change are denoted by “*”, “**” and “***” respectively. The genes without significantly different expression level were marked as “—”. Expression information of each DEG is listed when first mentioned or its name was boldly showed following the pathway name.
Fig. 6An overview of the molecular changes and their related functional outcomes induced by GA treatment in HCT116 cells.
Primers used in RT-qPCR and the fold change for the selected different expressed genes
| Name | NCBI_GI | Forward primer | Reverse primer | log2 fold change (GA12/C) | log2 fold change (GA24/GA12) | ||
|---|---|---|---|---|---|---|---|
| qRT-PCR | RNA-seq | qRT-PCR | RNA-seq | ||||
| ALOX5 | NM_00698.4 | TGGCGCGGTGGATTCATAC | CGTCCATCCCTCAGGACAAC | −1.12 | −1.9 | 1.32 | 1.83 |
| CAMK2B | NM_172084.2 | CGGAATTTCTCAGCCCGGAA | TGAGCCGGATGTAAGCGATG | −0.97 | −1.53 | 1.78 | 2.03 |
| PRKCG | NM_002739.4 | GCCACTAGGTGTCCCCAAC | GAGAATATCGGGCTCCGCTC | −1.03 | −1.61 | 1.12 | 1.52 |
| GNAZ | NM_002073.3 | AGCGGCTACGACCTGAAACT | AAGCAGATGGTGAGCGGGAT | −0.81 | −1.37 | 0.94 | 1.41 |
| FOS | NM_005252.3 | AGGGCTGGCGTTGTGAAGA | TCAGCAGGTTGGCAATCTCG | −1.36 | −1.99 | 1.56 | 1.99 |
| PLCD4 | NM_032726.3 | CAGGGCTTCACCATTGTCTT | TAACCGCTGAACTTCTTGGA | −0.78 | −1.42 | 1.11 | 1.4 |
| CYP4F2 | NM_023944.3 | CCTTGGACAGTCTACAGAAATGC | CTGAGTGGGGAGGGTGCGAC | −1.84 | −2.29 | 1.56 | 2.14 |
| PLAC1 | NM_001316887.1 | TACACGAGGAGTCTGTCAAGG | CAGCCAATCAGATAATGAACCA | −1.03 | −1.66 | 1.09 | 1.66 |
| CCNG2 | NM_004354.2 | CTGAGTTTGATTGAGGCTAC | GTTTCACCTTCATAAGAGCC | −1.22 | −1.8 | 1.17 | 2.05 |
| SESN3 | NM_001271594.1 | TTGACAAGAGGACCAAGTGC | AACTGGCTCCGCAAGAAAGA | −1.34 | −2.18 | 1.36 | 2.48 |
| KRT6A | NM_005554.3 | CATCCAAGAGGTCACCGTCA | GCAGGGTCCACTTTGTTTCC | 2.57 | 3.92 | −4.15 | −3.93 |
| MASP2 | NM_006610.3 | GAGGACATTGACGAGTGCCA | TGGAGAGTTTGGGATACGGC | 1.58 | 2.13 | −2.11 | 1.29 |